Shao, Yueming
Yang, Xinping
Yu, Jianhua
Wang, Xicheng
Wang, Jiangrong
Liu, Mei
Yang, Zongxing
Han, Jie
Zhang, Renfang
Liu, Li
Shen, Yinzhong
Sun, Meiyan
Wu, Luling
Zheng, Zhihang
Tang, Yang
Yang, Junyang
Wang, Zhenyan
Qi, Tangkai
Xu, Shuibao
Xun, Jingna
Sun, Jianjun
Song, Wei
Chen, Jun https://orcid.org/0000-0002-3850-4875
Clinical trials referenced in this document:
Documents that mention this clinical trial
Bone Mineral Density Changes in People with HIV Who had Immediate Switch Versus Deferred Switch from Tenofovir Disoproxil Fumarate-Based Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Multicenter, Open-Label, Randomized Clinical Trial
https://doi.org/10.1007/s40121-025-01262-8
Funding for this research was provided by:
Gilead Sciences (CO-US-380-5483)
Shanghai Public Health Clinical Center (RCJJ2025-10)
Shanghai Public Health Clinical Center (Grant Number KY-GW-2025-12)
Article History
Received: 24 August 2025
Accepted: 28 October 2025
First Online: 21 November 2025
Declarations
:
: Yueming Shao, Xinping Yang, Jianhua Yu, Xicheng Wang, Jiangrong Wang, Mei Liu, Zongxing Yang, Jie Han, Renfang Zhang, Li Liu, Yinzhong Shen, Meiyan Sun, Luling Wu, Zhihang Zheng, Yang Tang, Junyang Yang, Zhenyan Wang, Tangkai Qi, Shuibao Xu, Jingna Xun, Jianjun Sun, Wei Song, and Jun Chen declare that they have no competing interests. Jun Chen is an Editorial Board member of Infectious Diseases and Therapy. Jun Chen was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: The study was approved by the independent ethics committee of Shanghai Public Health Clinical Center (number: 2020-S187-02) and conformed to Good Clinical Practice guidelines and Declaration of Helsinki principles. This study was registered with ClinicalTrials.gov (NCT05122754). All participants provided written informed consent.